<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501825</url>
  </required_header>
  <id_info>
    <org_study_id>sha-16-11</org_study_id>
    <nct_id>NCT01501825</nct_id>
  </id_info>
  <brief_title>A Prospective, Comparative Study to Explore the Efficacy and Safety of the Five Channels Multiway Deep Transcranial Magnetic Stimulation (TMS) Device in Subjects With Major Depression Disorder (MDD)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brainsway-moach Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Multiway stimulator is a novel TMS stimulator with several new and unique properties.&#xD;
      Currently standard TMS devices include a single channel, and can operate only a single coil.&#xD;
      The Multiway stimulator includes five channels which can operate up to five independent TMS&#xD;
      coils, either simultaneously or sequentially.&#xD;
&#xD;
      The Multiway device may be used to obtain a differential activation of various brain regions.&#xD;
      For instance it can be used to induce high frequency stimulation of a certain brain region,&#xD;
      thus inducing facilitation, while simultaneously stimulate at low frequency in another brain&#xD;
      region, leading to inhibition.&#xD;
&#xD;
      The purpose of the study is to explore the efficacy and safety of Multiway deep TMS in&#xD;
      comparison to a single channel DTMS treatment in subjects with MDD.&#xD;
&#xD;
      Subjects will be treated with one of two designs of the study device (the Multiway Coil TMS&#xD;
      Device):&#xD;
&#xD;
        1. Single Channel with a coil placed over the left PFC (10 Hz).&#xD;
&#xD;
        2. Four channels: a. 10 Hz over the left PFC. b. 1 Hz over the right PFC. c. 10 Hz over the&#xD;
           left parietal cortex. d. 1 Hz over the right parietal cortex.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical antidepressant response</measure>
    <time_frame>day 20</time_frame>
    <description>Clinical antidepressant response at the end of the treatment, defined as a decline in Hamilton depression rating scale (HDRS-21) from the baseline rating by 50%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical antidepressant remission</measure>
    <time_frame>day 20</time_frame>
    <description>Clinical antidepressant remission at the end of the treatment, define as exit HDRS-21 &lt;10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic improvement</measure>
    <time_frame>day 20</time_frame>
    <description>Symptomatic improvement at the 4-week end point as measured with Hamilton Anxiety Rating Scale ( HARS), Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR) , Clinical Global Impression (CGI), Cognitive improvement measured by a computerized battery of tests (CANTAB).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>single channel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single Channel with a coil placed over the left PFC (10 Hz).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>four channels</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four channels:&#xD;
10 Hz over the left PFC.&#xD;
1 Hz over the right PFC.&#xD;
10 Hz over the left parietal cortex.&#xD;
1 Hz over the right parietal cortex.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>5 channels Multiway deep Transcranial Magnetic Stimulator</intervention_name>
    <description>During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)</description>
    <arm_group_label>single channel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>five channels Multiway deep Transcranial Magnetic Stimulation</intervention_name>
    <description>During the four channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together, and than 10 Hz- left parietal cortex, 1Hz - right parietal cortex together.&#xD;
10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)&#xD;
1 Hz protocol:&#xD;
1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)</description>
    <arm_group_label>four channels</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatient&#xD;
&#xD;
          -  Diagnosed by senior psychiatrist as suffering from major depression episode according&#xD;
             to DSM IV using the Structured Clinical Interview for DSM-4 (SCID).&#xD;
&#xD;
          -  Rating on HDRS-21&gt;20.&#xD;
&#xD;
          -  Age: 18-68 years.&#xD;
&#xD;
          -  Treated for the current depressive episode, at least four weeks, with at least one&#xD;
             antidepressant in accepted dose, without improvement, according to their medical chart&#xD;
             and ATHF ( antidepressant treatment history form) instruction guidelines .&#xD;
&#xD;
          -  Gave informed consent for participation in the study.&#xD;
&#xD;
          -  Negative answers on safety screening questionnaire for transcranial magnetic&#xD;
             stimulation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis as suffering from other diagnosis on axis 1 ( like: schizophrenia, bipolar&#xD;
             disorder, psychotic depression, geriatric depression).&#xD;
&#xD;
          -  Diagnosis as suffering from Severe Borderline Personality Disorder or hospitalized due&#xD;
             to exacerbation related to of borderline personality disorder.&#xD;
&#xD;
          -  Substantial suicidal risk as judged by the treating psychiatrist.&#xD;
&#xD;
          -  Attempted suicide in the past year.&#xD;
&#xD;
          -  Any current unstable medical or surgical illness.&#xD;
&#xD;
          -  History of seizure or heat convulsion.&#xD;
&#xD;
          -  History of epilepsy or seizure in first degree relatives.&#xD;
&#xD;
          -  History of head injury.&#xD;
&#xD;
          -  History of any metal in the head (outside the mouth).&#xD;
&#xD;
          -  Known history of any metallic particles in the eye, implanted cardiac pacemaker or any&#xD;
             intracardiac lines, implanted neurostimulators, surgical clips, cochlear implants or&#xD;
             any medical pumps.&#xD;
&#xD;
          -  History of hearing loss.&#xD;
&#xD;
          -  History of drug abuse or alcoholism in the last 6 month.&#xD;
&#xD;
          -  Pregnancy or not using a reliable method of birth control.&#xD;
&#xD;
          -  Systematic and metabolic unstable disorders.&#xD;
&#xD;
          -  Inadequate communication with the patient.&#xD;
&#xD;
          -  Under custodial care.&#xD;
&#xD;
          -  Participation in current clinical study or clinical study within 30 days prior to this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yechiel Levkovitz, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shalvata Medical Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yechiel Levkovitz, MD, Phd</last_name>
    <phone>097478644</phone>
    <email>ylevk@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>shalvata MHC</name>
      <address>
        <city>Hod HAsharon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shalvata Mental Health Center</name>
      <address>
        <city>Hod-HaSharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Yechiel Levkovitz, MD,Phd</last_name>
      <phone>972-9-7478644</phone>
      <email>ylevk@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Yechiel Levkovitz, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>December 27, 2011</study_first_submitted>
  <study_first_submitted_qc>December 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>July 3, 2012</last_update_submitted>
  <last_update_submitted_qc>July 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

